Melanoma patients were arbitrarily stratified into two groups according to clinical response to nivolumab therapy, as indicated in the Material and Methods paragraphs, to assess the correlation between CD4+CD26high T lymphocytes and clinical benefit to nivolumab. The gene discussed is CD4; the disease is melanoma.